Cervical cancer is the second most common cancer, only next to breast cancer, of women. Asian race each year with the number of cervical cancer is much greater than in Western World. At present, in addition to radiotherapy, outside the surgery, is the traditional chemotherapy. ADXS-HPV vaccine may be found in patients with advanced providing effective immunotherapy. GBP and Advaxis plans to execute the multi-center treatment of cervical cancer advanced Phase III clinical trials in 2014. GBP will continue to develop in Asia with Advaxis ADXS-HPV vaccine to treat head and neck cancer, anal cancer.